SF3B1 and myelodysplastic syndrome: Recently, based on the analysis of a comprehensive data set of 3479 patients, the International Working Group for the Prognosis of MDS suggested to create an SF3B1-mutant MDS subtype as a distinct disease subtype, characterized by (i) cytopenia, (ii) somatic SF3B1 mutation, (iii) isolated erythroid or multilineage dysplasia (for which RS will no longer be required for the diagnosis), (iv) bone marrow blasts <5% and peripheral blood blasts <1%, and (v) with selected concomitant genetic lesions as exclusion criteria [98].